Nanoform Finland Plc (NANOFH) - Total Assets
Based on the latest financial reports, Nanoform Finland Plc (NANOFH) holds total assets worth €57.13 Million EUR (≈ $66.79 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NANOFH total equity for net asset value and shareholders' equity analysis.
Nanoform Finland Plc - Total Assets Trend (2016–2024)
This chart illustrates how Nanoform Finland Plc's total assets have evolved over time, based on quarterly financial data.
Nanoform Finland Plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Nanoform Finland Plc's total assets of €57.13 Million consist of 61.0% current assets and 39.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €36.47 Million | 50.8% |
| Accounts Receivable | €1.68 Million | 2.3% |
| Inventory | €227.83K | 0.3% |
| Property, Plant & Equipment | €25.82 Million | 36.0% |
| Intangible Assets | €582.60K | 0.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Nanoform Finland Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Nanoform Finland Plc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanoform Finland Plc's current assets represent 61.0% of total assets in 2024, an increase from 51.1% in 2016.
- Cash Position: Cash and equivalents constituted 50.8% of total assets in 2024, up from 45.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 19.0% in 2016.
- Asset Diversification: The largest asset category is cash and equivalents at 50.8% of total assets.
Nanoform Finland Plc Competitors by Total Assets
Key competitors of Nanoform Finland Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
Nanoform Finland Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.32 | 7.41 | 11.49 |
| Quick Ratio | 4.30 | 7.37 | 11.49 |
| Cash Ratio | 0.00 | 5.06 | 0.00 |
| Working Capital | €23.93 Million | €41.96 Million | €56.21 Million |
Nanoform Finland Plc - Advanced Valuation Insights
This section examines the relationship between Nanoform Finland Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.84 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | -8.1% |
| Total Assets | €71.81 Million |
| Market Capitalization | $78.90 Million USD |
Valuation Analysis
Above Book Valuation: The market values Nanoform Finland Plc's assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Nanoform Finland Plc's assets decreased by 8.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nanoform Finland Plc (2016–2024)
The table below shows the annual total assets of Nanoform Finland Plc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €71.81 Million ≈ $83.95 Million |
-8.10% |
| 2023-12-31 | €78.13 Million ≈ $91.35 Million |
-22.36% |
| 2022-12-31 | €100.64 Million ≈ $117.66 Million |
+1.30% |
| 2021-12-31 | €99.35 Million ≈ $116.15 Million |
+34.47% |
| 2020-12-31 | €73.89 Million ≈ $86.38 Million |
+472.32% |
| 2019-12-31 | €12.91 Million ≈ $15.09 Million |
+57.27% |
| 2018-12-31 | €8.21 Million ≈ $9.60 Million |
+935.23% |
| 2017-12-31 | €792.93K ≈ $927.02K |
-6.13% |
| 2016-12-31 | €844.73K ≈ $987.57K |
-- |
About Nanoform Finland Plc
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) na… Read more